{
  "docId": "019de074-0cc8-70d5-8924-3a1b552a09af",
  "docSlug": "77b0d3b8437e31981ed49d98afb5005f",
  "documentTitle": "OmniAb | Investor Conference Presentation Deck | 43 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 43,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide illustrates the genetic engineering process of replacing endogenous Ig genes with human V gene segments while retaining rodent constant regions for immune robustness.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de074-0cc8-70d5-8924-3a1b552a09af/10",
  "deckHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af",
  "deckJsonHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af.json",
  "deckAnchorHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.02,
        "y": 0.655
      },
      "kind": "callout",
      "text": "Well-validated transgene design utilizes rodent constant regions for robust immune responses from the B-cell repertoire",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f219e2f8-754f-4d3f-a889-cf9c6cac5fa0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.43,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Genetic locus diagram showing human V, D, J segments combined with rodent constant regions, leading to chimeric antibody production and conversion to human antibody.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10929175-031d-4cb0-bb5c-42b0b36bdaf4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "list",
      "text": "Endogenous Ig genes inactivated\nExpression of full human V gene diversity\nStreamlined conversion into fully human molecule",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ff7cd44-eaa3-459b-8134-9e590a8cd1ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Geurts et al. Science 2009; Ménoret et al. Eur J Immunol 2010; Osborn et al. J. Immunol. 2013",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ec53a59-7b44-4ff1-ac94-bcb82f1775ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Rodent Platforms",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f38ba0f9-2ca0-4717-b83c-959ef168e855",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 7,
      "beatId": "3040f323-ee51-48d4-9506-f542b79a5e56",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-16 present OmniAb's platform and its capabilities.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d28165e9-330b-4b4c-9bd6-8826c981bf1a",
      "evidence": "Slides 6-16 imply that not using OmniAb's platform may lead to lower success rates for antibody medicines.",
      "position": 0,
      "objective": "Highlight the consequences of not adopting OmniAb's technology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}